Brain phospholipase C-diacylglycerol lipase pathway is involved in vasopressin-induced release of noradrenaline and adrenaline from adrenal medulla in rats

Eur J Pharmacol. 2004 Sep 19;499(1-2):99-105. doi: 10.1016/j.ejphar.2004.07.087.

Abstract

Recently, we reported that intracerebroventricularly (i.c.v.) administered arginine-vasopressin evokes the release of noradrenaline and adrenaline from adrenal medulla by brain thromboxane A2-mediated mechanisms in rats. These results suggest the involvement of brain arachidonic acid in the vasopressin-induced activation of the central adrenomedullary outflow. Arachidonic acid is released mainly by two pathways: phospholipase A2 (PLA2)-dependent pathway; phospholipase C (PLC)- and diacylglycerol lipase-dependent pathway. In the present study, therefore, we attempted to identify which pathway is involved in the vasopressin-induced release of both catecholamines from adrenal medulla using urethane-anesthetized rats. Vasopressin (0.2 nmol/animal, i.c.v.)-induced elevation of plasma noradrenaline and adrenaline was dose-dependently reduced by neomycin [0.28 and 0.55 micromol (250 and 500 microg)/animal, i.c.v.] and 1-[6-[[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-73122) [5 and 10 nmol (2.3 and 4.6 microg)/animal, i.c.v.] (inhibitors of PLC), and also by 1,6-bis(cyclohexyloximinocarbonylamino)hexane (RHC-80267) [1.3 and 2.6 micromol (500 and 1000 microg)/animal, i.c.v.] (an inhibitor of diacylglycerol lipase). On the other hand, mepacrine [1.1 and 2.2 micromol (500 and 1000 microg)/animal, i.c.v.] (an inhibitor of PLA2) was largely ineffective on the vasopressin-induced elevation of plasma catecholamines. These results suggest that vasopressin evokes the release of noradrenaline and adrenaline from adrenal medulla by the brain PLC- and diacylglycerol lipase-dependent mechanisms in rats.

MeSH terms

  • Adrenal Medulla / drug effects*
  • Adrenal Medulla / metabolism
  • Animals
  • Brain / enzymology*
  • Catecholamines / blood
  • Catecholamines / metabolism*
  • Cyclohexanones / pharmacology
  • Dose-Response Relationship, Drug
  • Epinephrine / blood
  • Epinephrine / metabolism
  • Estrenes / pharmacology
  • Injections, Intraventricular
  • Lipoprotein Lipase / antagonists & inhibitors
  • Lipoprotein Lipase / metabolism
  • Male
  • Neomycin / pharmacology
  • Norepinephrine / blood
  • Norepinephrine / metabolism
  • Phospholipases A / antagonists & inhibitors
  • Phospholipases A2
  • Pyrrolidinones / pharmacology
  • Quinacrine / pharmacology
  • Rats
  • Rats, Wistar
  • Signal Transduction*
  • Time Factors
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / metabolism
  • Vasopressins / pharmacology*

Substances

  • Catecholamines
  • Cyclohexanones
  • Estrenes
  • Pyrrolidinones
  • Vasopressins
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • 1,6-bis(cyclohexyloximinocarbonyl)hexane
  • Phospholipases A
  • Lipoprotein Lipase
  • Phospholipases A2
  • Type C Phospholipases
  • Quinacrine
  • Neomycin
  • Norepinephrine
  • Epinephrine